Table 5 Association of SOX2 and OCT3/4 expression with demographic, clinical, and laboratory data of ALL patients
From: Significance of OCT3/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia
Parameter | SOX2 expression (%) Median (min–max) | OCT3/4 expression (%) Median (min–max) | P1 | P2 | |
|---|---|---|---|---|---|
Gender | Male | 13.0 (0.3–67.9) | 1.2 (0.1–35.3) | 0.174 | 0.174 |
Female | 25.6 (3.1–71.6) | 2.1 (0.2–6.7) | |||
CD34% | Negative | 8.3 (0.3–46.2) | 0.9 (0.1–35.3) | 0.101 | 0.194 |
Positive | 20.2 (1.3–71.6) | 1.7 (0.1–19.5) | |||
Immunological subtype | B ALL | 13.0 (0.3–71.6) | 1.3 (0.1–19.5) | 0.034 | 0.792 |
T ALL | 39.0 (7.1–54.0) | 1.7 (0.3–35.3) | |||
Risk stratification | Favorable | 7.0 (0.3–34.5) | 1.0 (0.1–3.1) | <0.001 | 0.006 |
Unfavorable | 32.3 (6.6–71.6) | 2.5 (0.2–35.3) | |||
Response | CR | 10.8 (0.3–67.9) | 1.2 (0.1–13.2) | 0.017 | 0.038 |
Non-CR | 37.2 (6.6–71.6) | 3.3 (0.3–35.3) | |||
Relapse | Non relapsed | 9.7 (0.3–44.3) | 1.1 (0.1–3.6) | 0.019 | 0.049 |
Relapsed | 29.8 (7.1–67.9) | 1.9 (0.3–13.2) | |||
Living status | Lived | 9.6 (0.3–54.0) | 1.1 (0.1–6.6) | 0.005 | 0.006 |
Dead | 32.2 (5.8–71.6) | 2.8 (0.3–35.3) | |||